Business Context and Reporting Period
This Form 8-K filing by iSpecimen Inc. (ISPC) is dated July 1, 2021. The report details the closing of the over-allotment option related to the Company's initial public offering (IPO), which was originally consummated on June 21, 2021.
Key Financial Metrics
The filing reports specific proceeds from the IPO over-allotment exercise:
- Over-allotment Shares Issued: 337,500 shares of common stock.
- Offering Price: $8.00 per share.
- Gross Proceeds from Over-allotment: $2,700,000.
- Total IPO Gross Proceeds (Initial + Over-allotment): $20,700,000 ($18,000,000 from initial offering + $2,700,000 from over-allotment).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics beyond the IPO proceeds.
Material Changes
The primary material change reported is the full exercise of the underwriters' over-allotment option on June 30, 2021, with the closing of the additional share issuance occurring on July 1, 2021. This increased the total capital raised from the IPO by $2,700,000 compared to the initial June 21, 2021, closing.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the transactional event of the over-allotment exercise and references an attached press release (Exhibit 99.1) for further details.
Key Facts for Investor Verification
- Verify the total number of shares outstanding post-over-allotment (Initial 2,250,000 + Over-allotment 337,500).
- Confirm the net proceeds after deducting underwriting discounts and commissions, as only gross proceeds are listed in this text.
- Review the attached Press Release (Exhibit 99.1) for any additional commentary on the use of proceeds.
- Check subsequent filings for the impact of these proceeds on the Company's cash position and working capital.